Clinical Trials Logo

Filter by:
NCT ID: NCT02038673 Completed - Solid Tumors Clinical Trials

An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Start date: November 5, 2013
Phase: Phase 1
Study type: Interventional

The objectives of this study are to determine the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in participants with solid tumors.

NCT ID: NCT02037776 Completed - Clinical trials for Functional Dyspepsia

The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia

Start date: April 3, 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of Rikkunshito compared to placebo in Japanese subjects with Functional Dyspepsia (FD).

NCT ID: NCT02037477 Completed - Healthy Clinical Trials

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of TAK-438

Start date: January 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the acid-inhibitory effect of multiple oral doses of TAK-438 and the relative effect of TAK-438 versus two controls (esomeprazole and rabeprazole sodium) in healthy Japanese adult male participants with the CYP2C19 EM genotype.

NCT ID: NCT02036580 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

D2212C00002 J-Phase II Study

Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.

NCT ID: NCT02036047 Completed - Clinical trials for Postpolypectomy Bleeding

The Effectiveness of an Exclusive Cold Snare Polypectomy Snare for the Removal of Diminutive Colorectal Polyps

Start date: January 2014
Phase: N/A
Study type: Interventional

The use of an exclusive cold polypectomy snare enables a clean cut of diminutive colorectal polyps, resulting in an increase in the complete resection rate and a decrease in the adverse events.

NCT ID: NCT02035280 Completed - Clinical trials for Adult Spinal Deformity

Prospective Evaluation of Elderly Deformity Surgery

Start date: December 2013
Phase:
Study type: Observational

As the population continues to age, the prevalence of spinal deformity surgery for older patients is increasing. Questions regarding the suitability of these patients to undergo large spinal procedures and whether the outcomes merit the risks involved are not well known.

NCT ID: NCT02034110 Completed - Cancer Clinical Trials

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Start date: March 12, 2014
Phase: Phase 2
Study type: Interventional

This was a Phase II, open-label, non-randomized, multi-center study of oral dabrafenib in combination with oral trametinib in subjects with rare cancers harboring the BRAF V600E mutation including anaplastic thyroid cancer (ATC), biliary tract cancer (BTC), gastrointestinal stromal tumor (GIST), low grade (WHO G1/G2) glioma (LGG), high grade (WHO G3/G4) glioma (HGG), non-seminomatous germ cell tumors (NSGCT) / non-germinomatous germ cell tumors (NGGCT), adenocarcinoma of the small intestine (ASI), hairy cell leukemia (HCL) and multiple myeloma (MM).

NCT ID: NCT02033837 Completed - Clinical trials for Coronary Artery Disease

Evaluation of Cardiac CT Appropriateness at Second-generation 320-row CT

Start date: January 2013
Phase: N/A
Study type: Observational

The influence of the second-generation 320-row area-detector CT (ADCT) on the clinical indications and appropriateness of cardiac CT has not been adequately investigated. The purpose of the survey is to assess the distribution of appropriateness ratings and test outcomes of cardiac CT with second-generation ADCT.

NCT ID: NCT02032823 Active, not recruiting - Breast Cancer Clinical Trials

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

OlympiA
Start date: April 22, 2014
Phase: Phase 3
Study type: Interventional

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

NCT ID: NCT02032095 Completed - Clinical trials for End Stage Renal Disease

The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.

Start date: November 2013
Phase: Phase 2/Phase 3
Study type: Interventional

It is intended to examine the safety and efficacy of desensitization therapy by GB-0998 (intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of pre-transplant desensitization. Patients with positive FCXM-T after performing twice double filtration plasmapheresis (DFPP) therapy will receive GB-0998 1g/kg/day for four days.